Harnessing the potential synergy of combining radiation therapy and immunotherapy for thoracic malignancies.

C. Simone,A. Berman,S. Jabbour
DOI: https://doi.org/10.21037/tlcr.2017.04.05
2007-04-01
Translational Lung Cancer Research
Abstract:Thoracic malignancies are among the most lethal group of tumors. The most common thoracic malignancy, lung cancer, is histologically grouped as non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Nearly three-fifths of NSCLC patients and two-thirds of SCLC patients present with stage IV disease, and the median survival of both of these groups approximates one year (1,2). Malignant pleural mesothelioma is a malignancy of the mesothelial lining of the pleura and is associated with a median survival of 12–18 months (3,4). While thymic malignancies often present at an early stage, only approximately half of patients with stage III-IV thymoma will achieve a 5-year survival, and that percentage falls to approximately 30% for patients with stage III-IV thymic carcinoma (5,6).
What problem does this paper attempt to address?